mAbxience and HP partner to develop AI solution for biomanufacturing, aiming to optimize production process of monoclonal antibodies and biosimilars.

Unusual Whales
2025.12.04 08:03
In Madrid on December 4, 2025, mAbxience, a subsidiary of Fresenius, partnered with HP Inc., a leading technology company, to launch a groundbreaking project. This collaboration aims to create an advanced artificial intelligence (AI) tool that enhances the manufacturing process for monoclonal antibodies and biosimilars. The innovative project is set to revolutionize the production processes, with a focus on improving efficiency and quality control.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer